Back to Newsroom
Back to Newsroom

Aytu BioPharma to Report First Quarter Fiscal 2022 Results and Provide Business Update on November 15, 2021

Monday, 08 November 2021 08:05 AM

Aytu BioPharma, Inc.

ENGLEWOOD, CO / ACCESSWIRE / November 8, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that it will host a conference call and live webcast on November 15, 2021, at 4:30 p.m. ET. The Company will review accomplishments from the first quarter fiscal 2022 and provide an overview of its business and growth strategy.

The Company will file Form 10-Q after the markets close on November 15, 2021.

Conference Call Information

Toll Free: 877-545-0320 (Participant Access Code 664921)

International: 973-528-0002 (Participant Access Code 664921)

The webcast will be accessible live and archived at the following link, and on Aytu BioPharma's website, within the Investors section under Events & Presentations, at, for 90 days.

A replay of the call will be available for fourteen days. Access the replay by calling (877) 481-4010 (toll-free) or (919) 882-2331 (international) and using the replay access code 43552.

About Aytu BioPharma, Inc.

Aytu BioPharma is a specialty pharmaceutical company with a growing commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder (ADHD) and other common pediatric conditions. Aytu markets ADHD products Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING). The company's other pediatric products include Karbinal® ER (carbinoxamine maleate), an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency. The company's evolution has been driven by strategic in-licensing, acquisition-based transactions and organic product growth. Aytu is building a complimentary therapeutic development pipeline including AR101/enzastaurin, a prospective treatment for vascular Ehlers-Danlos Syndrome (VEDS), a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. There are no currently approved treatments for VEDS. To learn more, please visit

Contact for Media and Investors:

Sarah McCabe
Stern Investor Relations, Inc.
[email protected]

SOURCE: Aytu BioPharma, Inc.

Conference Call
Back to newsroom
Back to Newsroom
Share by: